ZURA BIO LIMITED Proceeds from Issuance Initial Public Offering
ZURA BIO LIMITED (ZURA) reported Proceeds from Issuance Initial Public Offering of $138.00 million for the 10-month period ending 2021-12-31, per its 10-K filed 2022-04-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceInitialPublicOffering · last filed 2022-04-25
- 2021-12-31: Proceeds from Issuance Initial Public Offering 10 month $138.00M.
- 2021-09-30: Proceeds from Issuance Initial Public Offering 7 month $138.00M.
| Period end | Proceeds from Issuance Initial Public Offering 7 month | Proceeds from Issuance Initial Public Offering 10 month |
|---|---|---|
| 2021-12-31 | $138.00M 10-K · filed 2022-04-11 | |
| 2021-09-30 | $138.00M 10-Q/A · filed 2022-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |